{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:19:56Z","timestamp":1783531196799,"version":"3.55.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.critrevonc.2021.103535","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T17:11:30Z","timestamp":1637341890000},"page":"103535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates"],"prefix":"10.1016","volume":"168","author":[{"given":"Rhea","family":"Arvind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivasa R.","family":"Chandana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5406-4155","authenticated-orcid":false,"given":"Danniel","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9368-6296","authenticated-orcid":false,"given":"Hani","family":"Babiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.critrevonc.2021.103535_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092283","article-title":"Permeabilizing cell membranes with electric fields","volume":"13","author":"Aguilar","year":"2021","journal-title":"Cancers."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0010","series-title":"Cent. Devices Radiol. Health Nd NovoTTF\u2122-100L Syst. - H180002","author":"Anon","year":"2020"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-43621-9","article-title":"Tumour-treating fields (TTFields): investigations on the mechanism of action by electromagnetic exposure of cells in telophase\/cytokinesis","author":"Berkelmann","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0020","first-page":"10","article-title":"Concurrent tumor treating fields (TTFields) and radiation therapy for newly diagnosed glioblastoma: a prospective safety and feasibility study","author":"Bokstein","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0025","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.26344","article-title":"Tumour treating fields in a combinational therapeutic approach","author":"Branter","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0030","series-title":"Internet]. Am. Cancer Soc","author":"Cancer Facts & Figures","year":"2020"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103535_bib0035","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","article-title":"Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial","volume":"20","author":"Ceresoli","year":"2019","journal-title":"Lancet Oncol [Internet]"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0040","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevE.64.026605","article-title":"Dielectrophoretic manipulation of macromolecules: the electric field","author":"Clague","year":"2001","journal-title":"Phys Rev E - Stat Phys Plasmas Fluids Relat Interdiscip Top"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0045","doi-asserted-by":"crossref","DOI":"10.1111\/nyas.12112","article-title":"Tumor treating fields: a new frontier in cancer therapy","author":"Davies","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0050","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-021-03755-1","article-title":"PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma","author":"Dono","year":"2021","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0055","article-title":"Safety of tumour treating fields delivery to the torso: meta analysis from TTFields clinical trials","author":"F. G","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0060","article-title":"Phase III trial of tumor treating fields (TTFields) together with temozolomide (TMZ) compared to temozolomide alone in patients with newly diagnosed glioblastoma (GBM)","author":"Farber","year":"2013","journal-title":"NeuroOncol"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125269","article-title":"Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit","author":"Gera","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.pan.2013.11.009","article-title":"Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields","author":"Giladi","year":"2014","journal-title":"Pancreatology"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0075","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminoncol.2014.09.006","article-title":"Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo","author":"Giladi","year":"2014","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0080","doi-asserted-by":"crossref","DOI":"10.1038\/srep18046","article-title":"Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in Cancer cells","author":"Giladi","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2005.03.070","article-title":"Harnessing dielectric forces for separations of cells, fine particles and macromolecules","author":"Gonzalez","year":"2005","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0090","doi-asserted-by":"crossref","DOI":"10.1119\/1.4766311","article-title":"Introduction to electrodynamics","author":"Griffiths","year":"2005","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0095","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2012.32.122","article-title":"Noninvasive application of alternating electric fields in glioblastoma: a fourth Cancer treatment modality","author":"Gutin","year":"2012","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0100","article-title":"IMST-26. Tumor treating fields exposure of tumor cells induce activation phenotype in immune cells","author":"Holtzman","year":"2016","journal-title":"NeuroOncol"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0105","series-title":"75 Years of Mortality in the United States, 1935-2010. NCHS Data Brief","author":"Hoyert","year":"2012"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0110","doi-asserted-by":"crossref","DOI":"10.3390\/biology5040044","article-title":"A cell biological perspective on past, present and future investigations of the spindle assembly checkpoint","author":"Joglekar","year":"2016","journal-title":"Biology."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.trsl.2019.10.003","article-title":"Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: implications for cancer therapy","author":"Karanam","year":"2020","journal-title":"Transl. Res."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0120","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-018-0079-9","article-title":"Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition","author":"Kessler","year":"2018","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0125","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-019-03361-2","article-title":"Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial","author":"Kim","year":"2020","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0130","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of Cancer cell replication by alternating electric fields","author":"Kirson","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0135","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","author":"Kirson","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0140","doi-asserted-by":"crossref","DOI":"10.1186\/1756-6649-9-1","article-title":"Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)","author":"Kirson","year":"2009","journal-title":"BMC Med. Phys."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0145","doi-asserted-by":"crossref","DOI":"10.1007\/s10585-009-9262-y","article-title":"Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs","author":"Kirson","year":"2009","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164051","article-title":"Enhancing predicted efficacy of tumor treating fields therapy of glioblastoma using targeted surgical craniectomy: a computer modeling study","author":"Korshoej","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0155","article-title":"Disruption of cell division within anaphase by tumor treating electric fields (TTFields) leads to immunogenic cell death","author":"Lee","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0160","series-title":"Abstract 709: Mitosis Interference of Cancer Cells by NovoTTF-100A Causes Decreased Cellular Viability","author":"Lee","year":"2013"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0165","article-title":"Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment","author":"Lee","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0170","doi-asserted-by":"crossref","DOI":"10.1109\/TBME.2020.2965883","article-title":"A theoretical study on the biophysical mechanisms by which tumor treating fields affect tumor cells during mitosis","author":"Li","year":"2020","journal-title":"IEEE Trans. Biomed. Eng."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103535_bib0175","doi-asserted-by":"crossref","DOI":"10.1088\/1478-3975\/9\/6\/065002","article-title":"Resting potential, oncogene-induced tumorigenesis, and metastasis: the bioelectric basis of cancer in vivo","volume":"9","author":"Lobikin","year":"2012","journal-title":"Phys. Biol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0180","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-017-2612-8","article-title":"Skin toxicities associated with tumor treating fields: case based review","author":"Lukas","year":"2017","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110193","article-title":"Tumor treating fields for high-grade gliomas","author":"Luo","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0190","article-title":"Tumor treating fields: concept, evidence and future","author":"M. P","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0195","article-title":"Clinical Cancer Advances 2020: annual report on progress against cancer from the American Society of Clinical oncology","author":"M.J","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103535_bib0200","article-title":"Association between cell membrane potential and breast cancer","volume":"15","author":"Marino","year":"1994","journal-title":"J. Immunother. Emphasis Tumor Immunol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0205","article-title":"30. Radiosurgery followed by tumor treating fields for brain metastases (1\u201310) from NSCLC in the phase 3 metis trial","author":"Mehta","year":"2020","journal-title":"Neuro-Oncol Adv"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0210","doi-asserted-by":"crossref","DOI":"10.1088\/0031-9155\/59\/15\/4137","article-title":"Predicting the electric field distribution in the brain for the treatment of glioblastoma","author":"Miranda","year":"2014","journal-title":"Phys. Med. Biol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0215","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminoncol.2015.02.024","article-title":"Corrigendum to \u201cClinical Practice Experience With Novo TTF-100ATM System for Glioblastoma: The Patient Registry Dataset (PRiDe).\u201d","author":"Mrugala","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0220","series-title":"NCCN Clinical Practice Guidelines in Oncology - Central Nervous System Cancers. NCCN","author":"NCCN","year":"2015"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0225","series-title":"Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)","author":"NCT02397928","year":"2015"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0230","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010110","article-title":"Alternating electric fields (TTFields) activate Ca v 1.2 channels in human glioblastoma cells","author":"Neuhaus","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0235","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","author":"Ostrom","year":"2019","journal-title":"Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103535_bib0240","article-title":"Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression","volume":"23","author":"Patel","year":"2021","journal-title":"Neoplasia U S"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0245","doi-asserted-by":"crossref","DOI":"10.1517\/13543784.2011.583236","article-title":"Tumor treating fields: concept, evidence and future","author":"Pless","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103535_bib0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2013.06.025","article-title":"A phase I\/II trial of Tumor treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer","volume":"81","author":"Pless","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0255","doi-asserted-by":"crossref","DOI":"10.1080\/1120009X.2020.1713508","article-title":"Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology","author":"Rezaei","year":"2020","journal-title":"J. Chemother."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.pan.2018.10.004","article-title":"Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase 2 study","author":"Rivera","year":"2019","journal-title":"Pancreatology"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0265","article-title":"ATPS-25p53 status dependence of tumor treating fields (TTFIELDS) efficacy against GLIOMA cancer cells","author":"Schneiderman","year":"2015","journal-title":"NeuroOncol"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0270","article-title":"Cancer statistics, 2018","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.adro.2019.08.005","article-title":"Tumor-treating field arrays do not reduce target volume coverage for glioblastoma radiation therapy","author":"Stachelek","year":"2020","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","author":"Stupp","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0285","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-Treating fields plus temozolomide vs temozolomide alone for glioblastoma a randomized clinical trial","author":"Stupp","year":"2015","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0290","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical trial","author":"Stupp","year":"2017","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0295","article-title":"Epidemiology and outcome of glioblastoma","author":"TAMIMI","year":"2017","journal-title":"In: Glioblastoma."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103535_bib0300","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-018-03057-z","article-title":"Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial","volume":"141","author":"Toms","year":"2019","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0305","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7819-12-162","article-title":"The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTFTM-100A system","author":"Turner","year":"2014","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0310","article-title":"Glioblastoma multiforme - an overview","author":"Urbanska","year":"2014","journal-title":"Wspolczesna Onkol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0315","article-title":"Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future? Ann","author":"Veliz","year":"2015","journal-title":"Transl. Med. Sunnyvale (Sunnyvale)"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103535_bib0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2018.07.1107","article-title":"Safety of TTFields applied to the torso: meta-analysis of 176 patients from four phase I-II trials","volume":"102","author":"Vergote","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103535_bib0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2018.07.018","article-title":"Tumor treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: results of the INNOVATE pilot study","volume":"150","author":"Vergote","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0330","article-title":"Immu-59. alternating electric fields (ttfields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-pd-1 therapy","author":"Voloshin","year":"2017","journal-title":"NeuroOncol"},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103535_bib0335","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12103016","article-title":"Tumor treating fields (Ttfields) hinder cancer cell motility through regulation of microtubule and acting dynamics","volume":"12","author":"Voloshin","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0340","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2017-0603","article-title":"Integration of tumor\u2010treating fields into the multidisciplinary management of patients with solid malignancies","author":"Wang","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2021.103535_bib0345","doi-asserted-by":"crossref","DOI":"10.1088\/0031-9155\/60\/18\/7339","article-title":"The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study","author":"Wenger","year":"2015","journal-title":"Phys. Med. Biol."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0350","doi-asserted-by":"crossref","DOI":"10.1109\/RBME.2017.2765282","article-title":"A review on tumor-treating fields (TTFields): clinical implications inferred from computational modeling","author":"Wenger","year":"2018","journal-title":"IEEE Rev. Biomed. Eng."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0355","doi-asserted-by":"crossref","DOI":"10.3340\/jkns.2019.0224","article-title":"The value of tumor treating fields in glioblastoma","author":"Zhang","year":"2020","journal-title":"J. Korean Neurosurg. Soc."},{"key":"10.1016\/j.critrevonc.2021.103535_bib0360","article-title":"EF-19, a post-approval registry study of tumor treating fields (TTFields) in recurrent glioblastoma (rGBM)","author":"Zhu","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282100322X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282100322X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:40:33Z","timestamp":1760902833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282100322X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":72,"alternative-id":["S104084282100322X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103535","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103535"}}